News & Updates
Excerpt from the Press Release: SAN DIEGO, March 18, 2021 (GLOBE NEWSWIRE) — Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) today announced that the first patient has been treated in its Phase 1b Amyloid Light Chain (AL) Amyloidosis study of STI-6129, an ADC which uses STI-5171, a fully human monoclonal antibody (mAb) from Sorrento’s G-MAB™ library.…
Read More
Excerpt from the Press Release: CAMBRIDGE, Mass., March 18, 2021 /PRNewswire/ –BOA Biomedical, a Miraki™ Innovation company, focused on rapidly diagnosing and treating some of the world’s deadliest infectious diseases has announced that the company will begin its First in Human clinical trial for GARNET. GARNET is an extracorporeal blood cleansing therapeutic capable of removing…
Read More
Excerpt from the Article: Ultrasound could be a disruptive tool in the fight against COVID-19, according to new research. A recent study published in the Journal of the Mechanics and Physics of Solids has found that the structure of the coronavirus may be vulnerable to the vibrations of an ultrasound with frequencies commonly used in…
Read More
Excerpt from the Press Release: SAN DIEGO, March 11, 2021 /PRNewswire/ — Persephone Biosciences Inc., a privately held, data-driven microbiome-focused biotechnology company, today announced the initiation of the VOICES clinical study to determine the impact of gut microbiome composition and function on the immune system and efficacy of COVID-19 vaccination. VOICES (Vaccine Observation to Include all…
Read More
Excerpt from the Press Release: PARIS and LEXINGTON, Mass., March 12, 2021 (GLOBE NEWSWIRE) — Sanofi Pasteur, the vaccines global business unit of Sanofi, and Translate Bio (NASDAQ: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company, today announced the start of the Phase 1/2 clinical trial for MRT5500, an mRNA vaccine candidate against SARS-CoV-2, the…
Read More
Excerpt from the Press Release: SAN DIEGO, March 15, 2021 (GLOBE NEWSWIRE) — aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced biomarker results from its Phase 2 double-blind, placebo-controlled clinical trial of its lead therapeutic candidate, ATYR1923, in hospitalized…
Read More
Excerpt from the Press Release: CAMBRIDGE, Mass.–(BUSINESS WIRE)–Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that the first participants have been dosed in the Phase 1 study of mRNA-1283, the Company’s next generation COVID-19 vaccine candidate. “We are pleased to begin this Phase 1 study of our…
Read More
Clinical Trials Ontario is hosting their annual conference titled “Clinical Trials During the COVID-19 Pandemic and Beyond” and the TrialStat team are exhibiting! “The CTO Conference is a leading Canadian forum to drive innovation in clinical trials, including leaders from the pharmaceutical and medical device industries, academic and healthcare leaders, representatives from patient groups, health…
Read More
Our March Ask Us Anything in Clinical Research Virtual Networking Event is next week! Join Heather and Christopher, and their guest, Malachi Bierstein from ScienceMedia for this exciting discussion on how effective site training can improve clinical trial performance! To register for your complimentary ticket, click the image or button below: Click Here to Register!
Read More
Excerpt from the Article: The East Coast Institute for Clinical Research (ECIR) is a site network with five offices throughout the Northeast Florida and Georgia conducting clinical trials across several therapeutic areas. Rebecca Goldfaden, VP of clinical operations for ECIR, has worked with more than 80 sponsor companies during her career in clinical research. She…
Read MoreRequest Your Demo Today!
From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?